Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

MLA

Innovative Medicines Initiative, et al. Biomarkers for Staging Fibrosis and Non-Alcoholic Steatohepatitis in Non-Alcoholic Fatty Liver Disease (the LITMUS Project): A Comparative Diagnostic Accuracy Study. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1431964523&authtype=sso&custid=ns315887.

APA

Innovative Medicines Initiative, European Commission, Vali, Y., Lee, J., Boursier, J., Petta, S., Wonders, K., Tiniakos, D., Bedossa, P., Geier, A., Francque, S., Allison, M., Papatheodoridis, G., Cortez-Pinto, H., Pais, R., Dufour, J.-F., Leeming, D. J., Harrison, S. A., Chen, Y., … on behalf of theLiver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. (2023). Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.

Chicago

Innovative Medicines Initiative, European Commission, Yasaman Vali, Jenny Lee, Jerome Boursier, Salvatore Petta, Kristy Wonders, et al. 2023. “Biomarkers for Staging Fibrosis and Non-Alcoholic Steatohepatitis in Non-Alcoholic Fatty Liver Disease (the LITMUS Project): A Comparative Diagnostic Accuracy Study.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1431964523&authtype=sso&custid=ns315887.